Forvia

25/11/25 -"The reduction in our FY25 EPS estimate is driven by two factors. First, we now include a €136m non-cash financial asset charge related to Symbio, the group’s hydrogen JV, which negatively impacts ..."

PDF page sample
Pages
59
Language
English
Published on
25/11/25
Download
You may also be interested by these reports :
25/11/25
The reduction in our FY25 EPS estimate is driven by two factors. First, we now include a €136m non-cash financial asset charge related to Symbio, the ...
24/11/25
We consider Ferrari a compelling buy-and-hold opportunity, with the current stock price presenting an attractive entry point after a significant ...
14/11/25
Two months ago, we looked at Investor performance under Trump II. Since Trump’s election, Industrivärden (ADD; Sweden) has followed a very similar ...
12/11/25
We reduced our FY25 sales estimate by 1.6% to €20.6bn, following the group’s updated and more precise guidance (previously €20.5–21.5bn). In ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO